Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies.

Trial Profile

Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Apr 2016 Treatment arms changed from 2 to 1, trial focus changed from AR to TU.
    • 13 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top